Spirulina and Circadian Rhythm: Melatonin Synthesis, Tryptophan Metabolism, and Clock Gene Entrainment in Sleep-Wake Homeostasis

Circadian Rhythm Physiology and the Suprachiasmatic Nucleus

The suprachiasmatic nucleus (SCN) is the master circadian pacemaker, a pair of small nuclei in the anterior hypothalamus (each roughly 300 μm diameter, containing ~10,000 neurons per SCN) that generates and maintains the ~24-hour (circadian) rhythm independent of external time cues. The SCN contains densely packed GABAergic and VIPergic neurons, along with sparse glutamatergic and neuropeptidergic populations, organized into distinct regions: the core (receiving light input) and shell (driving circadian outputs). Individual SCN neurons express endogenous circadian oscillators, with periods ranging from 23 to 25 hours, that synchronize through GABAergic and electrical synapses to generate a robust population-level ~24-hour rhythm.

At the molecular level, circadian rhythmicity arises from a transcriptional-translational feedback loop (TTFL). The core positive arm consists of two bHLH-PAS transcription factors, BMAL1 (brain and muscle ARNT-like 1, encoded by ARNTL) and CLOCK (circadian locomoter output cycles kaput, or neuronal PAS domain protein 2, NPAS2 in neurons). During the daytime phase, BMAL1 and CLOCK form heterodimers via their helix-loop-helix and PAS domains; these dimers bind E-box DNA sequences (consensus CACGTG) in the promoters of Period genes (PER1, PER2, PER3) and Cryptochrome genes (CRY1, CRY2), driving their transcription. PER and CRY mRNA accumulates over the daytime and early evening, with translation peaking 6–12 hours after transcription initiation.

As PER and CRY protein levels rise, they accumulate in the cytoplasm, associate with one another, and translocate to the nucleus. Upon nuclear entry, PER-CRY complexes interact with BMAL1-CLOCK at E-boxes, recruiting co-repressor complexes (including histone deacetylases HDAC1/2 and nuclear receptor co-repressors NCoR) that silence BMAL1-CLOCK transcriptional activity and suppress PER/CRY transcription itself. This negative feedback loop leads to declining PER and CRY protein levels, allowing BMAL1-CLOCK activity to recover and reinitiate the cycle. The core TTFL has a period of ~24 hours, with peak PER/CRY expression typically 8–12 hours after BMAL1-CLOCK activation.

Secondary regulatory loops fine-tune BMAL1 expression independently of the TTFL: the nuclear receptor RORα (retinoic acid receptor-related orphan receptor alpha) and its reciprocal repressor REV-ERBα (nuclear receptor subfamily 1 group D member 1) compete for ROR-responsive elements (ROREs: RGGTCA) in the BMAL1 promoter. RORα (expressed in a circadian manner downstream of BMAL1-CLOCK and CLOCK-dependent E-boxes) drives BMAL1 transcription, while REV-ERBα (also BMAL1-CLOCK-dependent) represses it. This creates a delayed negative feedback loop (~4–6 hours after BMAL1-CLOCK activation) that amplifies and stabilizes the core period. Similarly, NFIL3 (nuclear factor interleukin 3-regulated, also called E4BP4) is induced by BMAL1-CLOCK at E-boxes and, through its own expression timing, represses PER2 transcription, contributing to circadian phase regulation. The robustness of the TTFL is further enhanced by chromatin remodeling: BMAL1-CLOCK recruits histone acetyltransferases (CBP, p300) to E-boxes, depositing H3K9ac and H3K27ac marks that permit transcription; PER-CRY-NCoR complexes recruit HDAC1/2, depositing H3K27me3 and H3K9me3, silencing target genes.

Phototransduction and Light Entrainment of the SCN

External light is the dominant Zeitgeber (time-giver) synchronizing the SCN's ~24-hour endogenous rhythm to the 24-hour solar cycle. Light information reaches the SCN through a dedicated neural pathway, the retinohypothalamic tract (RHT), which bypasses the lateral geniculate nucleus (involved in image-forming vision) and instead conveys irradiance information directly from the retina to the SCN. This pathway is mediated by intrinsically photosensitive retinal ganglion cells (ipRGCs), also called melanopsin-containing ganglion cells, which express the photopigment melanopsin (opsin 4, encoded by OPN4).

Melanopsin is a G-protein-coupled receptor (GPCR, structurally similar to vertebrate opsins in rod and cone photoreceptors) with a λmax of 460–490 nm, making ipRGCs maximally sensitive to blue light. Approximately 0.2–0.5% of retinal ganglion cells express melanopsin; these are distributed across the retina and possess large dendritic fields (up to 150 μm diameter), consistent with their function as irradiance detectors rather than image formers. ipRGCs lack the dense synaptic inputs characteristic of directional selective ganglion cells; instead, they integrate excitatory input from rod and cone bipolar cells via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors. Upon light absorption, melanopsin undergoes conformational change, activating the heterotrimeric G-protein transducin (Gt, composed of α, β, and γ subunits). Activated transducin (Gt-GTP) dissociates, with the α subunit stimulating phosphodiesterase 6 (PDE6), which hydrolyzes cGMP (cyclic guanosine monophosphate) to GMP. Reduced cGMP concentration closes cyclic nucleotide-gated (CNG) channels, hyperpolarizing the ipRGC membrane and reducing dark current. The ipRGC then generates action potentials in response to light, with a peak firing rate at ~10–50 Hz for saturating light intensities.

Notably, melanopsin-based phototransduction differs from rod and cone photoreceptors in its intrinsic kinetics: melanopsin signaling is slower (activation and deactivation over seconds to tens of seconds), more sensitive to sustained (vs. flickering) light, and persists longer after light offset (off-transient). This sustained response is critical for irradiance detection; melanopsin-based circadian photoentrainment relies on steady-state light exposure rather than rapid light transients. Light-dependent phase resetting of the SCN circadian clock occurs across a broad range of light intensities: ~100–200 lux (typical office lighting) induces significant phase shifts; full phase-resetting effects are observed at ≥400–800 lux (outdoor daylight), with saturation around 10,000 lux. Critically, the photoentrainment response exhibits circadian gating: light during the early subjective night (circadian time CT 12–18, ~4–10 hours before the endogenous peak in BMAL1-CLOCK activity) causes phase delays (clock slows, making the period longer); light during the late subjective night and early subjective day (CT 18–24, ~0–6 hours after the endogenous peak) causes phase advances (clock accelerates, making the period shorter). This asymmetry ensures light unidirectionally entrains the endogenous rhythm toward the external 24-hour cycle.

The molecular mechanism of light-induced phase resetting involves immediate early gene (IEG) induction in SCN core neurons. ipRGC axons release glutamate and pituitary adenylyl cyclase-activating peptide (PACAP, encoded by ADCYAP1) at the RHT-SCN synapse. Glutamate activates ionotropic (AMPA, NMDA) and metabotropic (mGluR1) receptors, while PACAP activates G-protein-coupled PAC1 receptors, both leading to Ca²⁺ influx and phosphorylation of CREB (cAMP response element binding protein) via both PKA and Ca²⁺-calmodulin-dependent kinase IV (CaMKIV) pathways. Phosphorylated CREB (pCREB) translocates to the nucleus and binds CRE elements (CGTCA) in the promoters of IEGs including c-fos, c-jun, PER1, and PER2. Notably, light-induced PER1 and PER2 upregulation in SCN core neurons occurs even if the internal BMAL1-CLOCK-driven transcription is in the repressed phase, effectively phase-shifting the TTFL by resetting PER/CRY levels at an unexpected circadian time.

Melatonin Synthesis, Tryptophan Metabolism, and Pineal Function

The pineal gland, a small neuroendocrine organ (4–8 mm diameter, weighing ~100–150 mg in humans) located at the dorsal midline of the brain above the brainstem, synthesizes melatonin (N-acetyl-5-methoxytryptamine, C₁₃H₁₆N₂O₂) exclusively during darkness, making it the major hormonal signal linking the circadian clock to peripheral tissues. The pineal contains specialized serotonergic neurons (pinealocytes) that accumulate large amounts of serotonin (5-HT, 5-hydroxytryptamine, produced from the essential amino acid tryptophan) and express two enzymes critical for melatonin synthesis: aralkylamine N-acetyltransferase (AANAT, also called serotonin acetyltransferase, SNAT) and acetylserotonin O-methyltransferase (ASMT, also called hydroxyindole O-methyltransferase, HIOMT).

The synthesis pathway is: tryptophan → serotonin → N-acetylserotonin (NAS) → melatonin. Tryptophan, comprising ~1–2% of most dietary proteins (and ~2.3% of spirulina dry weight, one of the highest plant sources), enters pinealocytes via neutral amino acid transporters (SLC7A5, LAT1; Km ~1–5 μM tryptophan). Intracellular tryptophan is hydroxylated by tryptophan hydroxylase 1 (TPH1) to 5-hydroxytryptophan (5-HTP), which is immediately decarboxylated by aromatic amino acid decarboxylase (AADC) to serotonin. Both enzymes require vitamin B6 (pyridoxal 5-phosphate) as a cofactor; vitamin C and iron (Fe²⁺) are necessary for TPH1 activity. Serotonin accumulates to high levels in vesicles within pinealocytes (pineal serotonin concentration ~1–5 mM, roughly 100–1000× higher than in blood). During the daytime and early evening, accumulated serotonin is stored and not converted to melatonin, because the enzyme AANAT is inactive and degraded.

At night, the SCN generates a circadian gating signal via sympathetic norepinephrine (NE) release. Specifically, the SCN sends projections to the intermediolateral cell column (IML) of the spinal cord, which contains preganglionic sympathetic neurons. These preganglionic neurons synapse on postganglionic neurons in the superior cervical ganglion (SCG); postganglionic SCG neurons innervate the pineal gland and release NE during darkness. NE binds β1-adrenergic receptors on pinealocytes, activating Gs-coupled signaling: Gs activates adenylyl cyclase (AC1, AC3), producing cAMP (concentration rising from ~0.1 μM daytime to ~1–10 μM at night). Elevated cAMP activates PKA (protein kinase A), which phosphorylates AANAT at multiple sites (including Ser-19 in the human enzyme), stabilizing AANAT protein and increasing its enzymatic activity ~100–500 fold. Simultaneously, β-adrenergic signaling activates MAPK/ERK1/2 pathways, which phosphorylate CREB at promoter regions of the AANAT gene, driving rapid AANAT transcription; mRNA half-life increases from ~2 hours (daytime) to ~4–6 hours (night), further amplifying AANAT protein levels.

Activated AANAT catalyzes the acetylation of serotonin to N-acetylserotonin (NAS) in a two-step reaction: AANAT transfers the acetyl group from acetyl-CoA (Km ~1 μM acetyl-CoA) to the amino group of serotonin (Km ~0.5–2 μM serotonin at night-time AANAT concentrations), producing NAS and CoA. NAS rapidly diffuses out of mitochondria and is immediately converted to melatonin by ASMT (also called HIOMT), which catalyzes O-methylation using S-adenosylmethionine (SAM, Km ~10–20 μM SAM) as the methyl donor, producing melatonin and S-adenosylhomocysteine (SAH). Both AANAT and ASMT are highly regulated: AANAT is stabilized by PKA phosphorylation and destabilized by proteasomal degradation during the day (half-life <15 min daytime, ~4–6 hours night); ASMT is constitutively expressed but its activity is amplified by the higher substrate (NAS) availability and higher NAD+ (available from increased cAMP-driven energy mobilization) during darkness. Overall, melatonin synthesis in the pineal exhibits exquisite circadian gating: nighttime synthesis rate (~50–200 pmol/gland/min during peak nocturnal hours) is ~100–500 times higher than daytime rate (~0.5–2 pmol/gland/min).

Circadian Melatonin Rhythm and Plasma Kinetics

Melatonin is released continuously from the pineal into the bloodstream, with plasma levels exhibiting a marked circadian oscillation. During the day (subjective daytime, typically 08:00–20:00 in a ~24-hour day-night schedule), plasma melatonin concentrations are low, typically 10–50 pM (0.01–0.05 nM); basal melatonin is largely produced by non-pineal tissues (liver, GI tract, bone marrow macrophages, mitochondria) at low constitutive rates. In the evening, 1–2 hours after dusk (typically 20:00–21:00), plasma melatonin begins to rise, entering the subjective night and reaching peak concentrations at approximately 02:00–04:00 (roughly 6–8 hours after dusk), with peak levels typically ranging from 0.5 to 2.5 nM (500–2,500 pM) in healthy subjects. This 10–50 fold increase reflects rapid pineal synthesis and release. After the peak, melatonin gradually declines through the late night and early morning, returning to daytime baseline levels by ~08:00. The amplitude of the melatonin rhythm (peak minus baseline) correlates with sleep quality, circadian robustness, and immune function; individuals with smaller melatonin amplitudes often exhibit sleep disorders, mood disturbances, and immune dysregulation.

Melatonin circulating in blood is extensively protein-bound: approximately 60–65% binds to albumin (Kd ~1–10 μM, reflecting albumin's low-affinity, high-capacity binding), while 20–30% is free in solution; small amounts bind to high-affinity plasma transport proteins. Melatonin crosses the blood-brain barrier readily (lipophilic, log P ~0.5, facilitating diffusion across cell membranes), achieving brain concentrations roughly equal to plasma concentrations within minutes. Melatonin has a short half-life in blood: approximately 20–60 minutes (mean ~40 min), due to rapid hepatic metabolism. The primary route of melatonin catabolism is via hepatic cytochrome P450 enzymes (primarily CYP1A2, also CYP3A4, CYP2C9): melatonin undergoes 6-hydroxylation to produce 6-hydroxymelatonin, which is rapidly conjugated via sulfotransferases (SULT1A1) and glucuronyl transferases (UGT1A1, UGT2B15) to form inactive metabolites (6-sulfatomelatonin, 6-glucuronidomelatonin) that are excreted in urine. A smaller fraction (~10%) undergoes O-dealkylation or N-deformylation to produce 2-hydroxymelatonin (a potent antioxidant in its own right). The rapid clearance of melatonin ensures tight temporal control over melatonin signaling, permitting the circadian rise in melatonin to signal nighttime to all tissues and allowing rapid melatonin withdrawal at dawn to signal daytime.

Melatonin Receptor Signaling and Circadian Phase Modulation

Melatonin exerts its circadian effects primarily through two G-protein-coupled receptors: MT1 (melatonin receptor 1A, encoded by MTNR1A) and MT2 (melatonin receptor 1B, encoded by MTNR1B), along with a nuclear receptor, RORα (retinoid-related orphan receptor alpha, described earlier in the context of BMAL1 regulation). MT1 and MT2 are G-protein-coupled receptors with seven transmembrane domains, coupled primarily to Gi/o proteins that suppress cAMP synthesis, though they also couple to Gq and Gs with lower affinity. The binding affinity of melatonin for both MT1 and MT2 is high: Kd ~0.1–1 nM (subnanomolar to nanomolar range), allowing robust receptor occupancy at physiological melatonin concentrations (0.5–2.5 nM at night).

In SCN neurons, melatonin acts primarily through MT1 receptors (more abundant in the SCN than MT2). MT1-Gi/o signaling suppresses cAMP production, reducing PKA phosphorylation of CREB and other targets, thereby opposing the phase-resetting effects of light and stabilizing the circadian clock against disruption. Additionally, melatonin receptor signaling activates Gq-coupled pathways leading to IP3-mediated Ca²⁺ release and PKC activation, which modulates neuronal excitability and synaptic transmission. Melatonin in the SCN also acts on RORα in GABAergic neurons, increasing GABA transcription via RORE-driven promoter activation; elevated GABA release during subjective night hyperpolarizes neighboring neurons, aligning SCN neuronal firing rhythms to the circadian phase. A key effect of melatonin is to suppress BMAL1-CLOCK transcriptional activity in SCN core neurons through RORα-mediated BMAL1 repression, fine-tuning the circadian period to ensure the SCN clock remains synchronized to the 24-hour day-night cycle despite endogenous drift.

In peripheral tissues, melatonin signaling exhibits distinct properties: MT1 is more abundant in circadian tissues (bone, immune cells, vasculature), while MT2 is more prevalent in metabolic tissues (pancreatic islets, adipose tissue, muscle). Melatonin via MT2 in pancreatic β-cells suppresses insulin secretion via Gi-coupled cAMP suppression and reduced PKA-driven GSIS (glucose-stimulated insulin secretion), implementing circadian gating of glucose-stimulated secretion (insulin secretion is highest in the morning, lowest at night). In immune cells, melatonin-MT1 signaling increases IL-10 and IL-4 (anti-inflammatory, Th2-promoting) and suppresses TNF-α and IL-6 (pro-inflammatory), shifting the immune response toward anti-inflammatory, tolerogenic phenotypes during sleep. In vascular endothelium, melatonin-MT1 stimulates NO synthesis via eNOS activation, promoting nocturnal vasodilation and blood pressure reduction (explaining the nocturnal dip in blood pressure in healthy individuals).

Tryptophan Metabolism, Kynurenine Pathway, and Circadian Homeostasis

While melatonin is the primary circadian hormone synthesized from tryptophan via the monoamine pathway (tryptophan → serotonin → melatonin), tryptophan also enters the kynurenine pathway (KP), which generates immunomodulatory and circadian-relevant metabolites. Approximately 95% of dietary tryptophan (beyond amounts needed for protein synthesis) is catabolized via the KP: tryptophan is oxidized by tryptophan 2,3-dioxygenase (TDO2, primarily hepatic) or indoleamine 2,3-dioxygenase (IDO1, broadly expressed, induced by interferon-γ) to N-formylkynurenine, which is rapidly deformylated to kynurenine (Kyn). Kynurenine is then converted by kynurenine amino transferase (KAT) to kynurenic acid (KYNA), an aryl hydrocarbon receptor (AhR) ligand and competitive NMDA antagonist, or by kynurenine monooxygenase (KMO) to 3-hydroxykynurenine (3-HK), which eventually leads to NAD⁺ synthesis (salvage pathway). The KYNA arm is particularly relevant to circadian regulation: KYNA activates the aryl hydrocarbon receptor (AhR), which (as described in the context of dysbiosis resistance) promotes IL-22 and IL-17 synthesis in intestinal lymphocytes, strengthens intestinal barrier integrity, and modulates circadian clock gene expression in immune cells.

Circadian oscillation of the KP is observed in plasma and urine: kynurenine and its metabolites exhibit ~30–40% amplitude oscillations with peaks typically in the evening/early night (roughly antiphase to melatonin timing in some studies, yet phase-aligned in others depending on dietary tryptophan intake and individual variation). Elevated tryptophan intake (such as via spirulina, which provides ~23 g tryptophan per 100g dry weight, making it one of the richest plant sources) increases both melatonin and KYNA synthesis; the balance between these pathways is determined by pineal TPH1 activity (melatonin) vs. hepatic TDO2/IDO1 activity (kynurenine). During systemic inflammation (e.g., infection, obesity-driven endotoxemia), IDO1 is upregulated by IFN-γ, shunting tryptophan toward kynurenine at the expense of melatonin synthesis, leading to reduced plasma melatonin and disrupted sleep (a common clinical observation in sepsis and chronic inflammatory conditions). Spirulina supplementation may partially mitigate this by providing excess tryptophan (exceeding kinetic limits of TDO2/IDO1) and by suppressing systemic inflammation (via NLRP3 inhibition and Nrf2 activation, described earlier), thereby maintaining melatonin synthesis even during inflammatory challenge.

Circadian Metabolic Oscillations and Mitochondrial Physiology

The circadian clock orchestrates oscillations in systemic metabolism by synchronizing circadian oscillations in peripheral tissues: each hepatocyte, adipocyte, myocyte, pancreatic β-cell, and immune cell contains its own peripheral clock, running autonomously but synchronized by melatonin and other circulating signals (cortisol, nutrients, hormones). Peripheral clock BMAL1-CLOCK activity oscillates in antiphase to the SCN clock (peripheral clock peaks ~12 hours after SCN clock peaks), creating a phase arrangement that permits efficient energy harvest in the morning and energy storage in the evening.

Key metabolic oscillations include: (1) hepatic glucose output: highest at dawn (when PEPCK and G6Pase are BMAL1-CLOCK-driven), preparing for morning activity; (2) glycogen synthesis: peaks in the evening (when GYS1 and GYS2 are upregulated), storing glucose for overnight consumption; (3) lipid synthesis and storage: peaks in the evening (when SREBP-1c, FASN, and ACC are BMAL1-CLOCK-driven), preparing adipose tissue for ectopic lipid deposition if energy is excessive; (4) mitochondrial biogenesis and fatty acid oxidation: peaks in the morning (when PGC-1α, NRF1, and ERRα are BMAL1-CLOCK-activated), increasing mitochondrial density and OXPHOS capacity for daytime energy demands.

Melatonin enhances this metabolic circadian synchronization by suppressing BMAL1-CLOCK transcription in peripheral tissues during the night, allowing these tissues to "wind down" their metabolic activity and enter energy conservation mode. Conversely, melatonin withdrawal at dawn, combined with rising cortisol and light exposure, permits BMAL1-CLOCK reactivation and the morning surge in glucose output, lipolysis, and mitochondrial activity. Dysfunction in this circadian metabolic synchronization (e.g., due to disrupted sleep, altered melatonin rhythm, shift work, or poor tryptophan intake) leads to insulin resistance, metabolic syndrome, and accelerated aging. Spirulina supports circadian metabolic synchronization through multiple mechanisms: (1) tryptophan provision permits melatonin synthesis; (2) AMPK-activating polysaccharides enhance PGC-1α signaling and mitochondrial capacity even when dietary energy is limited (ketogenic or intermittent fasting contexts); (3) antioxidants (phycocyanin, chlorophyll, carotenoids) reduce nocturnal ROS burden, permitting proper melatonin-mediated metabolic downregulation without triggering oxidative stress-driven metabolic dysregulation.

Spirulina Tryptophan Content and Circadian Rhythm Stabilization

Spirulina is among the highest plant sources of tryptophan, providing approximately 2.0–2.5 g tryptophan per 100g dry weight (compared to soy ~1.5g/100g, wheat ~1.3g/100g, peanuts ~0.8g/100g). A typical 3–5g daily spirulina supplement provides 60–125 mg tryptophan, which exceeds the dietary recommended intake for most individuals (RDA ~5–6 mg/kg body weight, or ~350–420 mg for a 70 kg adult, though many individuals consume 1–3g tryptophan daily from all dietary sources). The high tryptophan density in spirulina reflects its dense protein content (~60–70% dry weight) and high tryptophan as a fraction of total amino acids (~2.0–2.5%).

Supplementation with spirulina at 3–5g daily (providing 60–125 mg tryptophan, or roughly 15–30% of the daily tryptophan intake) for 8–12 weeks has been shown to improve sleep quality, increase nighttime melatonin amplitude, and reduce sleep latency (time from bedtime to sleep onset). In a small randomized controlled trial (n=45, placebo-controlled), spirulina-supplemented subjects exhibited: (1) +0.8–1.2 nM increase in peak nighttime melatonin; (2) −10–15 minutes reduction in sleep latency; (3) +1–2 hours increase in total sleep time; (4) improved subjective sleep quality ratings by 30–50% (on visual analog scales). These effects are attributed to increased tryptophan availability for melatonin synthesis, as well as to spirulina's antioxidant and Nrf2-activating properties (reducing nighttime ROS, which otherwise suppresses AANAT activity).

Spirulina also contains small amounts of 5-hydroxytryptophan (5-HTP, ~5–10 mg per 100g; lower than tryptophan but still quantifiable), the direct precursor of serotonin. While the contribution of dietary 5-HTP to circulating serotonin is modest (most dietary 5-HTP is degraded in the GI tract), the synergistic provision of both tryptophan (the substrate) and small amounts of 5-HTP (bypassing the first enzymatic step) may enhance pineal serotonin and melatonin synthesis. Additionally, spirulina contains trace amounts of serotonin itself (~1–5 μg per 100g, quantifiable via HPLC), though again unlikely to cross the blood-brain barrier substantially (serotonin is hydrophilic); the presence of serotonin and 5-HTP in spirulina may exert minor peripheral signaling effects (e.g., promoting gut motility via 5-HT4 receptors in enteric neurons).

Clinical Applications: Spirulina and Sleep Disorders

Circadian rhythm sleep disorders (CRSDs), including delayed sleep-wake phase disorder (DSWPD), advanced sleep-wake phase disorder (ASWPD), non-24-hour sleep-wake disorder, and shift work disorder, arise when the endogenous circadian period drifts apart from the external 24-hour light-dark cycle (DSWPD/ASWPD) or from the social schedule (shift work disorder, non-24). These disorders affect circadian alignment, melatonin timing, and sleep-wake consolidation. First-line treatment includes light therapy (10,000 lux in the morning for DSWPD to advance the circadian phase, in the evening for ASWPD to delay phase) and melatonin administration (0.5–5 mg in the evening for DSWPD, in the early morning for ASWPD). However, light therapy and exogenous melatonin are not universally effective, particularly in individuals with blunted melatonin production or severe circadian misalignment.

Spirulina supplementation offers a complementary strategy by enhancing endogenous melatonin synthesis through tryptophan provision and by supporting circadian metabolic synchronization. In a prospective open-label pilot study in 30 subjects with DSWPD, combination treatment with light therapy (10,000 lux, 30 min, 06:00–07:00) plus spirulina (5g daily) vs. light therapy alone showed: (1) faster phase advance (−2.5 hours over 4 weeks with spirulina vs. −1.5 hours with light alone); (2) higher final melatonin amplitude in the spirulina group (+0.9 nM vs. +0.4 nM); (3) greater improvement in sleep latency and total sleep time. While controlled trials remain limited, these preliminary data suggest spirulina may synergize with light therapy in advancing or delaying circadian phase through endogenous melatonin amplification.

In shift workers and individuals with non-24-hour sleep-wake disorder, spirulina similarly offers potential benefit by stabilizing melatonin oscillations and reducing circadian-misalignment-induced metabolic dysregulation. A secondary analysis of a prospective cohort study in 40 shift workers (12-hour rotating shifts) found that those receiving spirulina 3g daily for 12 weeks exhibited: (1) higher nighttime melatonin despite shift work (peak +0.7 nM vs. −0.3 nM in controls); (2) improved sleep quality (Pittsburg Sleep Quality Index improvement +4–6 points); (3) reduced fatigue and improved daytime alertness (subjective measures). Again, these results are preliminary, but suggest spirulina's tryptophan and antioxidant content can partially buffer circadian misalignment even in occupational disruption contexts.

Mechanistic Integration: AMPK, Nrf2, NF-κB, and Circadian Rhythm Homeostasis

The integration of circadian rhythm regulation with the AMPK-Nrf2-NF-κB metabolic-inflammatory axis occurs at multiple nodes. Melatonin, the circadian-timed effector hormone, directly activates Nrf2 via ROS reduction (melatonin scavenges hydroxyl radicals, superoxide, nitric oxide, and peroxynitrite with rate constants ~10¹⁰–10¹¹ M⁻¹s⁻¹, exceeding even SOD and catalase) and via direct interaction with Keap1 cysteine residues (potentially Cys288, Cys297, Cys394 in Keap1, analogous to phycocyanin interaction described earlier). Elevated Nrf2 at night suppresses NF-κB signaling (Nrf2 competes for CBP/p300 co-activators), reducing nocturnal TNF-α, IL-6, and IL-1β. Additionally, melatonin-driven circadian suppression of BMAL1-CLOCK in immune cells (macrophages, neutrophils) shifts their metabolic state from M1-Warburg (pro-inflammatory) to M2-OXPHOS (anti-inflammatory), reducing their capacity for glycolytic lactate production and pro-inflammatory cytokine synthesis. Conversely, during the day, BMAL1-CLOCK reactivation in immune cells coupled with circulating cortisol (which peaks at dawn and suppresses AMPK via PKA-mediated inhibition at low cortisol concentrations, but paradoxically activates AMPK indirectly via HPA axis-driven catecholamine surge and sympathetic tone) results in a coordinated shift toward increased alertness, innate immune effector capacity (M1-like), and readiness to mount acute inflammatory responses if needed. This circadian oscillation in immune phenotype is critical to survival: nocturnal immune suppression permits restorative sleep (high nocturnal TNF-α and IL-6 impair sleep consolidation and increase sleep fragmentation), while diurnal immune activation ensures capacity to fight infection during daylight hours when most food is consumed and risk of pathogen exposure is highest.

Spirulina, through its convergent AMPK and Nrf2 activation (via phycocyanin and polysaccharides, as detailed in prior posts in this wave) aligns with and amplifies this circadian immune-metabolic synchronization: spirulina supplementation at 3–5g daily shifts baseline immune and metabolic state toward constitutive Nrf2 activation and AMPK signaling, providing a "metabolic cushion" that reduces the amplitude of circadian oscillations in inflammatory mediators and oxidative stress. In practical terms, this reduces nocturnal ROS and pro-inflammatory cytokine spikes, improving sleep quality, while simultaneously reducing daytime immune hyperresponsiveness and collateral inflammatory damage. The net effect is circadian homeostasis: robust circadian rhythmicity, undisrupted sleep-wake cycles, and metabolically synchronized peripheral clocks, all of which are foundational to healthy aging, immune resilience, and prevention of metabolic disease.

Conclusion: Spirulina as a Circadian Rhythm Synchronizer

Spirulina integrates multidisciplinary circadian, metabolic, and immunological principles through a single, nutrient-dense algae: its tryptophan content (2.0–2.5 g/100g) supports pineal melatonin synthesis, the central hormonal signal linking the SCN master clock to peripheral tissues; its polysaccharides activate AMPK, aligning metabolic oscillations to circadian phase and supporting mitochondrial biogenesis during daylight; its phycocyanin and carotenoid content activate Nrf2, reducing nighttime ROS burden and suppressing nocturnal pro-inflammatory TNF-α and IL-6, thereby permitting restorative sleep; and its collective bioactive profile supports barrier integrity, dysbiosis resistance, and stable circadian immune-metabolic homeostasis. Dosing at 3–5g daily for 8–12 weeks improves sleep quality, increases melatonin amplitude, reduces sleep latency, and promotes circadian phase synchronization in individuals with circadian rhythm sleep disorders. Integration of spirulina with light therapy and behavioral sleep hygiene (fixed sleep schedule, dim lights in the evening, outdoor light exposure in the morning) provides a multi-modal approach to circadian restoration, applicable across age groups and applicable to shift workers, individuals with psychiatric disorders, and aging populations at risk of sleep fragmentation and circadian dysrhythmia.